Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19

Abstract

Background: This study aims to evaluate the real-world effectiveness of regdanvimab on clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19). Methods: This retrospective observational study included 152 patients (89 received regdanvimab and 63 did not) diagnosed with mild to moderate COVID-19 between August 2021 and October 2021 and admitted to Armed Forces Goyang Hospital. We collected information on the use of regdanvimab, remdesivir, dexamethasone, and supplemental oxygen; symptom severity score (SSS); and laboratory test results. A linear mixed-effects model was used to test the effectiveness of regdanvimab usage on SSS and the results of laboratory tests. A multivariate logistic regression model was used to calculate the odds ratio (OR) for additional therapeutic options, such as remdesivir, dexamethasone, and supplemental oxygen. Results: The patients who received regdanvimab were older, showed a higher rate of vaccination, and had a higher Charlson comorbidity index, initial body temperature, and percentages of pneumonia at admission. The use of regdanvimab showed no interactive effects on the SSS and laboratory findings. Older age, male sex, obesity, high initial body temperature, and the presence of pneumonia at admission were associated with increased ORs for the use of these additional treatments. The use of regdanvimab reduced the probability of requiring additional therapies such as remdesivir, dexamethasone, and oxygen supplementation by 90.3% (95% confidence interval (CI), 60.3–97.6), 85.8% (95% CI, 34.2–96.9), and 89.8% (95% CI, 48.3–98), respectively. Conclusions: Regdanvimab usage was well tolerated and was associated with a decreased probability of requiring remdesivir, dexamethasone, and oxygen therapy. However, changes in SSS were not significantly different by the drug usage.

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis

“…The electronic search identified a total of 7 studies 2 , 4 , 5 , 6 , 7 , 8 , 9 , one of which were randomized controlled trials and the others were retrospective studies. This meta-analysis included 1350 patients in the regdanvimab group, 1983 patients in the control group.…”

Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis

“…Out of a total of 138 studies after removing duplicates, 12 full-text studies were assessed for eligibility. Four studies were excluded due to irrelevant data, 22,27 combination therapy 28 or review article. 29 Finally, 8 studies 16,20,21,[30][31][32][33][34] including 2 RCTs 16,32 and 6 observational studies 20,21,30,31,33,34 with 4793 patients were considered in the meta-analysis.…”

Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis

“…This finding is consistent with the pooled estimate of six studies, which demonstrated the effectiveness of sotrovimab in decreasing the need for mechanical ventilation due to COVID-19 [ 23 ]. The existing literature also suggests that other mAb therapies, such as regdanvimab [ 28 ] and casirivimab/imdevimab, may be effective in reducing the need for supplemental oxygen therapy and mechanical ventilation in patients with COVID-19, compared to control participants.…”